date:Jul 04, 2012
lity revealed significant violations of the CGMP regulations for dietary supplements.
FDA Warning Letter: FDA warns Oklahoma Respiratory Care, Inc. (Norman, OK) that an October 2011 inspection of the companys pharmaceutical manufacturing facility identified significant violations of Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals.
Outbreak Alert (Oregon): Three Central Oregon residents were hospitalized with symptoms of botulism, contracted at a private barb